A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Clinical trial NCT07221500 · RECRUITING

Trial details

NCT number: NCT07221500
Sponsor: Nurix Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Start date: 2025-10-15
Primary completion: 2028-01-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.